Hot Topics in Internal Medicine
|
|
- Jason Perry
- 8 years ago
- Views:
Transcription
1 49th Annual Meeting Disclosure Hot Topics in Internal Medicine Denise Kelley, PharmD, BCPS Internal Medicine Pharmacist UF Health Jacksonville I do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies for this continuing education activity, or any affiliation with an organization whose philosophy could potentially bias my presentation OWNING CHANGE: Taking Charge of Your Profession Objectives News You Can Use Identify and evaluate recent primary literature pertinent to the practice of Internal Medicine Compare and contrast latest literature recommendations with present standards of care Incorporate current evidence-based recommendations into clinical practice Cardiology Alcoholic Hepatitis Alcoholic Hepatitis Alcoholic Hepatitis (AH) Controversial management 30-50% mortality Maddrey s discriminant function (MDF) 4.6 x (PT-control PT) + bilirubin Prednisolone 40 mg Qday* Pentoxifylline 400 mg TID* Maddrey (1978): Reduced mortality Meta-analysis did not favor use Reduced early mortality if MDF 32 Akriviadis (2000): Reduced mortality Reduced hepatorenal syndrome as cause of death (50% vs. 92%) Score 32 believed to merit drug therapy Combination COPE (2012): No survival benefit Mathurin (2013): No survival benefit Lucey MR, et al. N Engl J Med 2009;360: *Given for 28 days Lucey MR, et al. N Engl J Med 2009;360:
2 Alcoholic Hepatitis Prednisolone or Pentoxifylline for Alcoholic Hepatitis - STOPAH (n=276) Prednisolone (n=277) 1103 patients Pentoxifylline (n=276) Primary outcome: Mortality at 28 days 45/269 38/266 50/258 Combination (n=274) 35/260 (17%) Secondary outcomes: (14%) Mortality (19%) or liver transplant (13%) at 90 days, 1 year; adverse events Thursz MR, et al. NEJM 2015;372: Alcoholic Hepatitis Endpoints Pentoxifylline No Pentoxifylline p-value 28-day mortality 85/518 (16%) 83/535 (16%) NS 90-day mortality 139/478 (29%) 146/490 (30%) NS or transplant 1-year mortality or transplant 205/365 (56%) 216/382 (57%) NS Endpoints Prednisolone No Prednisolone p-value 28-day mortality 73/526 (14%) 95/527 (18%) day mortality 144/484 (30%) 141/484 (29%) NS or transplant 1-year mortality or transplant 210/371 (57%) 211/376 (56%) NS Thursz MR, et al. NEJM 2015;372: Alcoholic Hepatitis Statistical evaluation Incidence of infection and mortality Exclusion criteria Possible short-term mortality benefit Prednisolone Considerations: Pentoxifylline No mortality benefit 1. Reduced blood flow through liver 2. Portal vein hypertension 3. Mesenteric splanchnic vasodilation Compensatory Responses: 1. Increase sympathetic response 2. Increase reninangiotensinaldosterone system 3. May form collaterals Thursz MR, et al. NEJM 2015;372: Krag A, et al. Gut 2012;61(7): Role of non-selective beta blocker (NSBB) in cirrhosis Hemodynamic Reduce sympathetic response Decreases cardiac output Splanchnic vasoconstriction Prevent esophageal varices Non-hemodynamic Reduce bacterial translocation Krag A, et al. Gut 2012;61(7): Secondary prevention of esophageal varices Lebrec (1981): 96% in propranolol arm vs. 50% on placebo free of GIB at 1 year Targeted a 25% reduction in heart rate Primary prevention of esophageal varices Pascal (1987): 74% in propranolol arm free of GIB at 1 year vs. 39% in placebo Targeted a 20-25% reduction in heart rate Evolving role of beta-blockers Varying literature of beneficial or detrimental effect in the following: hepatorenal syndrome (HRS) spontaneous bacterial peritonitis (SBP) Window hypothesis Ge PS, et al. Journ of Hepatol 2014; 60:
3 Non Selective Beta-Blocker in Spontaneous Bacterial Peritonitis Inclusion 607 patients with cirrhosis, undergoing first paracentesis 362 no NSBB, 245 NSBB Primary outcome Impact of NSBB on transplant-free survival Development of HRS Secondary outcomes Rates of HRS, Rates of AKI, Hemodynamic parameters No effect on survival Improve survival Reduce survival Hypothesis Development of SBP closes the window of opportunity for NSBB treatment Ge PS, et al. Journ of Hepatol 2014; 60: Mandorfer M, et al. Gastroenterol 2014;146: Non Selective Beta-Blocker in Spontaneous Bacterial Peritonitis Transplant Free Survival mortality after SBP diagnosis in NSBB group HR (p=0.007) Acute Kidney Injury incidence of AKI in NSBB group (17/86, 20% vs. 7/90, 8%; p=0.021) Hepatorenal Syndrome incidence of HRS in NSBB group (20/83, 24% vs. 9/82, 11%; p=0.027) Conclusions NSBB provides benefit up to development of SBP Worsened transplant-free survival in pts with SBP SBP may close the therapeutic window of benefit Considerations Limitations of study Management after SBP resolves Mandorfer M, et al. Gastroenterol 2014;146: Mandorfer M, et al. Gastroenterol 2014;146: News You Can Use Progression to ESRD Cardiology Bone/Mineral disorders Anemia Acidosis Phosphate binders Vitamin D products Calcimimetic Erythropoeitin stimulating agents (ESA) Iron supplementation Bicarbonate supplementation Resolves with dialysis 3
4 Ferric Citrate Phosphate Binders Iron based Ferric citrate Ferric citrate 441 patients on dialysis 52 weeks Active control Calcium based Non elemental Primary outcome: safety, iron parameters Calcium acetate Calcium carbonate Sevelamer carbonate Lanthanum carbonate 4 week washout period 192 patients on dialysis re-randomized Magnesium carbonate Magnesium based Aluminum based Aluminum hydroxide Ferric citrate 4 weeks Primary outcome: mean change in phosphorus Lewis JB, et al. J Am Soc Nephrol 2014;26 Lewis JB, et al. J Am Soc Nephrol 2014;26 Ferric Citrate Ferric Citrate Well tolerated, minimal side effects Comparable to standard phosphorus binders FDA approved Fall 2014 Cost comparison Increased iron stores, reduced IV iron and ESA dosing Outcome Ferric citrate Active control p-value Ferritin (ng/ml) 858 ( ) 576 ( ) <0.001 TSAT (%) 36.0 ( ) 28.0 ( ) <0.001 IV iron (mg/wk) 12.9 ( ) 26.8 ( ) <0.001 ESA dose (units/wk) 5303 ( ) 6954 ( ,375) 0.04 Considerations of iron supplementation Lewis JB, et al. J Am Soc Nephrol 2014;26 Lewis JB, et al. J Am Soc Nephrol 2014;26 Vitamin D Vitamin D Benefits of Vitamin D Maintain skeletal health Pleiotropic effects Immunomodulating, antitumor, renal protective, CV Vitamin D2 ergocalciferol Vitamin D3 cholecalciferol 25(OH)D 1,25(OH) 2 D 25-hydroxyvitamin D levels Interpretation (ng/ml) <20 Deficiency Insufficiency 30 Sufficiency Inactive Vitamin D Vitamin D analogs Active Vitamin D Ergocalciferol Doxercalciferol Calcitriol Cholecalciferol Paracalcitol Kramer H, et al. Am J Kidney Dis 2014;64(4): Kramer H, et al. Am J Kidney Dis 2014;64(4):
5 Vitamin D Vitamin D3 vs. doxercalciferol First randomized controlled trial in 2010, CKD stages 3-4 Vitamin D3 had greater impact on PTH levels in CKD stage 3 25-OH supplementation in dialysis Inconsistent effects of 25(OH)D supplementation 25(OH)D levels 30 associated with maximal PTH suppression Recommendations No consensus from guidelines, clinical judgement DIVINE and VITAL studies ongoing Vitamin D Dialysis Infection and Vitamin D in New England 105 dialysis patients with 25(OH)D 32 ng/ml Ergocalciferol weekly (n=36) Ergocalciferol monthly (n=33) daily (n=36) 25(OH)D levels >32 ng/ml in 90.9%, 64.5%, 35.3% Similar rate of hospitalization, infection, CV events All-cause mortality lower in ergocalciferol arms (p=0.02) Kramer H, et al. Am J Kidney Dis 2014;64(4): Bhan I, et al. J Am Soc Nephrol 24: 2013 [Abstract] News You Can Use Cardiology (ID) 850,000 hospital admissions 14.2 million outpatient visits Most common pathogens: Staphylococcus aureus Streptococcus pyogenes 2014 IDSA updated guidelines TMP/ SMX Doxy Clinda Skin and soft tissue infections Miller LG, et al. N Engl J Med 2015;372: ID Skin/Soft tissue ID Skin/Soft tissue Clindamycin 300 mg TID (n=264) 524 patients with cellulitis or abscess 10 days duration TMP/SMX 1 DS BID (n=260) Outcomes: Cure rates at 1-month follow-up, adverse events Conclusions Similar cure rates Similar adverse events Considerations Dosing strategies Limitations to study Exclusion criteria Choosing an agent Miller LG, et al. N Engl J Med 2015;372: Miller LG, et al. N Engl J Med 2015;372:
6 ID Probiotics Antibiotic associated diarrhea (AAD) common occurrence 15-39% caused by Clostridium difficile (CD) Mechanism not fully elucidated -High-risk antibiotics -Cumulative antibiotic exposure -Prolonged hospital stay, previous hospitalization -Age 65 years -Proton pump inhibitor, nasogastric tube -Antimicrobial stewardship -Infection control -Probiotics? ID Probiotics PLACIDE (2013) Inpatient adults 65 years randomized Lactobacillus/bifidobacterium vs. placebo Incidence of AAD within 8 wks, CD within 12 wks Probiotic (n=1493) (n=1488) Incidence of AAD 159 (10.8%) 153 (10.4%) Incidence of CD 12 (0.8%) 17 (1.2%) No difference in side effects Insufficient evidence to support use of probiotic Allen SJ, et al. Lancet 2013;382: Allen SJ, et al. Lancet 2013;382: ID Probiotics News You Can Use Considerations of PLACIDE in clinical practice Complexity of lactobacillus preparations 170 species, 17 subspecies Safety of probiotics Serious infections rare in literature, associated with severe comorbidities (malignancy, GI conditions) Update in Clinical s journal Cardiology Allen SJ, et al. Lancet 2013;382: Cardiovascular (CV) Dual antiplatelet therapy (DAPT) recommendations Bare metal: Continue for 1 month, ideally 1 year Drug eluting: Continue for 3-6 months depending on type, up to 1 year if low risk of bleed Bare metal: Continue for 1 month, ideally 1 year Drug eluting: Continue for at least 12 months Bare metal: Continue for at least 12 months Drug eluting: Continue for at least 12 months CV DAPT Benefit of dual antiplatelet therapy beyond 1 year Randomization after drug eluting stent placed 12 months 18 months 3 months Aspirin + thienopyridine Primary outcomes: Stent thrombosis Aspirin + placebo vs. Aspirin + thienopyridine Aspirin alone Major cardiovascular or cerebrovascular events Kushner FG, et al. Circulation 2009;120: Mauri L. N Engl J Med 2014;371:
7 CV DAPT CV DAPT Results 12-month (n=4941) Increased bleeding in 30-month group 1.6% vs. 2.5%, p=0.001 Higher all cause mortality in 30-month group 1.5% vs. 2.0%, p= month (n=5020) p-value Stent thrombosis 65 (1.4%) 19 (0.4%) p<0.001 Major events 285 (5.9%) 211 (4.3%) p<0.001 Increased events in 3-month observational group Dual anti-platelet therapy showed reduced events with higher risk of bleed compared to aspirin alone Conclusions/Considerations Study population selected Duration of DAPT still in question Choice of thienopyridine Mauri L. N Engl J Med 2014;371: Mauri L. N Engl J Med 2014;371: CV PEGASUS CV - PEGASUS Median time since MI 1.7 years MI in last 1-3 years Ticagrelor 90 mg BID Ticagrelor 60 mg BID All patients received lowdose aspirin Age >50 years, at least 1 major risk factor Median follow-up duration 33 months Ticagrelor 90 mg (n=7050) Ticagrelor 60 mg (n=7045) (n=7067) Composite 493 (7.85%) 487 (7.77%) 578 (9.04%) endpoint Major bleeding 127 (2.60%) 115 (2.30%) 54 (1.06%) Primary outcome: composite of cardiovascular death, myocardial infarction (MI), stroke Bonaca MP, et al. N Eng J Med 2015;372: Fatal bleeding 32 (0.63%) 33 (0.71%) 30 (0.60%) Bonaca MP, et al. N Eng J Med 2015;372: CV PEGASUS Cardiovascular Ticagrelor + low-dose aspirin >1 year after MI Reduced risk of CV death, MI, or stroke Aspirin Thienopyridine Anticoagulant WOEST Aspirin/clopidogrel/warfarin vs. clopidogrel/warfarin Less bleeding, no increased stent thrombosis Increased risk of major bleeding PIONEER-AF PCI DAPT vs. triple therapy with rivaroxaban In progress - evaluating incidence of bleeding and CV events Bonaca MP, et al. N Eng J Med 2015;372: Dewilde WJ, et al. Lancet 2013;381: Gibson CM, e al. Am Heart J 2015;169:
8 - Apixaban Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis) Atrial fibrillation *Dose adjust if two of three criteria are met Dosing 150 mg PO BID CrCl <30: 75 mg BID CrCl <15: 20 mg PO Qday CrCl <50: 15 mg Qday CrCl <15: 5 mg PO BID 2.5 mg PO BID if >80 yrs, <60 kg, or SCr >1.5* DVT/PE Heparin x 5-10 days, 150 mg PO BID 15 mg PO BID x 3 wk 20 mg PO Qday 10 mg PO BID x 1 wk 5 mg PO BID Dosing CrCl <30: CrCl <30: CrCl <30: Adam SS, et al. Ann Intern Med 2012;157: Apixaban dosing in hemodialysis (HD) 8 patients with ESRD, 8 healthy individuals 5 mg dose HD 7-day washout HD 5 mg dose Levels obtained up to 72 hours after each dose % Drug recovered: ESRD: 7% of dose Healthy: 18% of dose 39% higher AUC in ESRD patients FDA approved dosing regimen for hemodialysis for AF Wang X, et al. Clinical Pharm in Drug Dev [Abstract] New developments/future uses Headlines In AH, no mortality benefit with pentoxifylline, possible short-term mortality benefit with prednisolone Beta-blocker in SBP could lead to increased development of HRS and increased mortality Newly approved ferric citrate is comparable phosphate binder while reducing iron and ESA requirements Inactive vitamin D should be utilized in ESRD patients for its nutritional efficacy benefit and mortality benefit Linkins LA, et al. J Thromb Thrombolysis 2014; 38: Gulick RM, et al. Dept of Health and Human Services 2015; 216 Headlines No difference between TMP/SMX or clindamycin for skin and soft tissue infections (SSTI) Questionable benefit of probiotics in preventing Clostridium difficile infections Cardiovascular Continuing DAPT beyond 12 months associated with reduced CV events, increased bleeding Literature surrounding triple therapy in the pipeline Headlines Apixaban has FDA approved dosing for atrial fibrillation in ESRD patients based on small study population Potential role of new anticoagulants in HIT Rivaroxaban and apixaban are contraindicated with protease inhibitors per HIV guidelines 8
9 References References 1. Lucey MR, Mathurin P, Morgan T. Alcoholic Hepatitis. N Engl J Med 2009;360: Thursz MR, Richardson P, Allison M, Austin A, et al. Prednisolone or Pentoxifylline for Alcoholic Hepatitis. N Engl J Med 2015;372: Krag A, Wiest R, Albillos A, Gluud LL. The Window Hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012;61(7): Ge PS, Runyon BA. The changing role of beta-blocker therapy with patients in cirrhosis. Journ of Hepatol 2014; 60: Mandorfer M, Bota S, Schwabl P, Bucsics T, et al. Nonselective beta-blocker increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterol 2014;146: Lewis JB, Sika M, Koury MJ, Chuang P, et al. Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis. J Am Soc Nephrol 2014; Kramer H, Berns JS, Choi MJ, Martin K, et al. 25-Hydroxyvitamin D Testing and Supplementation in CKD: An NKF-KDOQI Controversies Report. Am J Kidney Dis 2014;64(4): Miller LG, Daum RS, Creech CB, Young D, et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated N Engl J Med 2015;372: Allen SJ, Wareham K, Wang D, Bradley C, et al. Lactobacilli and bifidobacterium in the prevention of antibiotic-associated diarrhea and clostridium difficile diarrhea in older inpatients: a randomized, double blind, placebo controlled, multicentre trial. Lancet 2013;382: Stevens DL, Bisno AL, Chambers HF, Dellinger EP, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the s Society of America. Clin Infect Dis 2014; Evans C, Safdar N, Chopra T, Goldstein EJC, et al. Clin Infect Dis 2015;60(suppl 2):S66-S Wang X, et al. Presented at 2012 American College of Clinical Pharmacology Annual Meeting September 23 rd 25 th San Diego, California. Clinical Pharm in Drug Dev, 1: 175. [Abstract]. 13. Kushner FG, Hand M, Smith SC, King SB, et al Focused: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention. Circulation 2009;120: Mauri L Kereiakes DJ, Yeh RW, Driscoll-Shempp P, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med 2014;371: Bonaca MP, Bhatt DL, Cohen M, Steg PG, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Eng J Med 2015;372: Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY). N Engl J Med 2009; 361: Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF). N Engl J Med 2011; 365: Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE). N Engl J Med 2011; 365: Pradaxa (dabigatran) [package insert]. Boehringher Ingleheim, Ridgefield (CT): October Xarelto (rivaroxaban) [Package Insert]. Janssen Pharmaceuticals, Titusville (NJ): December Eliquis (apixaban) [Package Insert]. Bristol Myers Squibb, Princeton (NJ). December Gulick RM, Hirsch MS, Lane HC, Pau AK, et al. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at ; Bhan I, Dobens DA, Trottier CA, Wenger JB, et al. The DIVINE Trial: Dialysis Infection and Vitamin D in New England. J Am Soc Nephrol 24:2013 [Abstract: SA-PO1082). 49th Annual Meeting Hot Topics in Internal Medicine Denise Kelley, PharmD, BCPS Internal Medicine Pharmacist UF Health Jacksonville OWNING CHANGE: Taking Charge of Your Profession 9
Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationL'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001
L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationOral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Abbreviations AF: Atrial fibrillation ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationMedication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
More informationNovel OACs: How should we use them?"
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationWhat s New in Stroke?
5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario
More informationEliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More information} Most common arrhythmia. } Incidence increases with age. } Anticoagulants approved for AF
Deniz Yavas, PharmD PGY-2 Ambulatory Care Pharmacy Resident Detroit Veterans Affairs Medical Center } Most common arrhythmia 0.4-1% of Americans (2.2 mil people) 1,2 } Incidence increases with age 6% (65
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More informationThe New Kids on the Block: Oral Anticoagulants
The New Kids on the Block: Oral Anticoagulants Lauren E. Odum, PharmD, BCPS Clinical Assistant Professor UMKC School of Pharmacy at MU April 11, 2014 Objectives Be able to Understand the major trials leading
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationTriple thérapie anti-thrombotique chez le coronarien. Y Cottin Dijon
Triple thérapie anti-thrombotique chez le coronarien Y Cottin Dijon «Dans la vie, rien n est à craindre, tout est à comprendre» Marie Curie Epidémiologie Aspirine/Clopidogrel/Ticagrelor/Prasugrel Durée?
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More information9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban
Identify the FDA approved direct oral anticoagulants (DOACs) Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services Distinguish the differences in the dosing of DOACs for various indications Describe
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationRx Updates New Guidelines, New Medications What You Need to Know
Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationOptimal Duration of Dual Antiplatelet Therapy
Optimal Duration of Dual Antiplatelet Therapy Luis A Guzman, MD, FACC, FSCAI Associate Professor of Medicine Director, Cardiac and Vascular Cath Lab University of Florida College of Medicine - Jacksonville
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationCardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationxaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.
Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationEINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012
EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationConserva)ve Treatment of PE/ DVT
Conserva)ve Treatment of PE/ DVT Amir Kaki, MD FACC FSCAI Asst Prof of Medicine Wayne St SOM Medical Director Cardiac Catheteriza)on Lab Heart Hospital DMC Detroit, MI Incidence Acute pulmonary embolism
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationWhat You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
More informationFinancial Disclosures
Financial Disclosures Consulting: AstraZeneca, Bayer, Boehringer Ingleheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, Ortho/McNeill, Pfizer,
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationElisabetta Toso, MD Dipartment of Medical Sciences University of Turin
Security and efficacy of Rivaroxaban in real life in the prevention of the stroke in non valvular AF patients: presentation of the results of the international study Xantus Elisabetta Toso, MD Dipartment
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationAntiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
More informationRivaroxaban. Practical Experience in the Cardiology Setting. Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013
Rivaroxaban Practical Experience in the Cardiology Setting Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013 Overview of phase III clinical trials of new oral anticoagulants
More informationThe importance of adherence and persistence: The advantages of once-daily dosing
The importance of adherence and persistence: The advantages of once-daily dosing Craig I. Coleman, PharmD Professor, University of Connecticut School of Pharmacy Storrs, CT, USA Conflicts of interest Dr
More informationUse of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Cheryl Ea, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationIntroduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
More informationOral Anticoagulation in Older Persons The Next Generation
Oral Anticoagulation in Older Persons The Next Generation Luis Viana B.Sc. Phm., Pharm D (candidate), M.Ed., ACPR, CGP Clinical Consultant Pharmacist, Medical Pharmacies Group Limited Adjunct Clinical
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationGUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY
BLOOD CONSERVATION STRATEGIES IN CARDIAC SURGERY: MORE IS BETTER GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY DIMITRIOS V. AVGERINOS MD, PhD, FACS, FACC Department of Cardiac Surgery,
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationXarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason
Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical
More informationPrevention of thrombo - embolic complications
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More information